Bertrand Jean-Claude, PhD
Primary Axis:
Cancer
Email:
Email contact form Research Focus:
Cancer drug research has been aided tremendously by the recent identification of the role of several kinases in signal transduction pathways involved in the progression of many cancers including several types of leukemias, prostate, ovarian, brain, breast and lung carcinomas. The primary objective of our laboratory is to develop new models designed to enhance the efficacy of signal transduction inhibitors in the treatment of refractory tumours.Signal transduction inhibitors, refractory tumours, kinases, fluorescence microscopy, flow cytometry, combi-targeting, leukemia, breast and prostate carcinomas
External Website:
External Website Keywords:
Signal transduction inhibitors, refractory tumours, kinases, fluorescence microscopy, flow cytometry, combi-targeting, leukemia, breast and prostate carcinomas
Location:
Royal Victoria Hospital Publications:
Matheson SL, Brahimi F, Jean-Claude BJ. The combi-targeting concept: intracellular fragmentation of the binary epidermal growth factor (EGFR)/DNA targeting "combi-triazene" SMA41. Biochemical Pharmacology 2004, 67: 1131-1138
Banerjee R, Rachid Z, McNamee J, Jean-Claude BJ. Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase and an alkylating agent: a novel tumour targeting concept. Journal of Medicinal Chemistry 2003; 46:5546-5551.
Brahimi F, Matheson S, Dudouit F, Tari A, McNamee J, Jean-Claude BJ. Inhibition of EGFR-mediated signaling by the Combi-Triazene BJ2000, A new probe for the combi-targeting concept. Journal of Pharmaceutical and Experimental Therapies 2002; 303: 1-9.
